1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Vinogradova, O. Haas, T. Plow, E.F. Qin, J. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 1 90.00 90.00 90.00 1.000 1.000 1.000 C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking US Proc.Natl.Acad.Sci.USA PNASA6 0040 0027-8424 97 1450 1455 10.1073/pnas.040548197 10677482 A structural basis for integrin activation by the cytoplasmic tail of the alpha IIb-subunit. 2000 10.2210/pdb1dpk/pdb pdb_00001dpk 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 2395.579 INTEGRIN ALPHA-IIB SUBUNIT CYTOPLASMIC DOMAIN 1 syn polymer no no KVGFFKRNRPPLEEDDEEGE KVGFFKRNRPPLEEDDEEGE A polypeptide(L) n n n n n n n n n n n n n n n n n n n n database_2 pdbx_nmr_exptl_sample_conditions pdbx_nmr_software pdbx_struct_assembly pdbx_struct_oper_list repository Initial release Version format compliance Version format compliance Data collection Database references Derived calculations Experimental preparation 1 0 2000-02-28 1 1 2008-04-27 1 2 2011-07-13 1 3 2022-02-16 _database_2.pdbx_DOI _database_2.pdbx_database_accession _pdbx_nmr_exptl_sample_conditions.pressure_units _pdbx_nmr_software.name SOLUTION STRUCTURE OF THE CONSTITUTIVELY ACTIVE MUTANT OF THE INTEGRIN ALPHA IIB CYTOPLASMIC DOMAIN. RCSB Y RCSB 1999-12-27 REL The peptide was chemically synthesized. The sequence of residues is naturally found in the platelets of homo sapiens (human). sample USED DPC (DODECYL-PHOSPHOCHOLINE) MICELLES back calculated data agree with experimental NOESY spectrum 30 16 2D NOESY DQF-COSY 2D TOCSY 50 mM NACL 5.0 1 atm 298 K simulated annealing 1 minimized average structure 3MM PEPTIDE VARIAN collection VNMR 5.5 DELAGLIO, F. processing NMRPipe GARRETT, D.S. data analysis PIPP BRUNGER, A.T. structure solution X-PLOR 3.2 BRUNGER, A.T. refinement X-PLOR 3.2 500 Varian UNITYPLUS LYS 1 n 1 LYS 1 A VAL 2 n 2 VAL 2 A GLY 3 n 3 GLY 3 A PHE 4 n 4 PHE 4 A PHE 5 n 5 PHE 5 A LYS 6 n 6 LYS 6 A ARG 7 n 7 ARG 7 A ASN 8 n 8 ASN 8 A ARG 9 n 9 ARG 9 A PRO 10 n 10 PRO 10 A PRO 11 n 11 PRO 11 A LEU 12 n 12 LEU 12 A GLU 13 n 13 GLU 13 A GLU 14 n 14 GLU 14 A ASP 15 n 15 ASP 15 A ASP 16 n 16 ASP 16 A GLU 17 n 17 GLU 17 A GLU 18 n 18 GLU 18 A GLY 19 n 19 GLY 19 A GLU 20 n 20 GLU 20 A author_defined_assembly 1 monomeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 1 A A O HD22 PHE ASN 4 8 1.55 2 A A O HD22 PHE ASN 4 8 1.46 3 A A O HD22 PHE ASN 4 8 1.56 4 A A O HD22 PHE ASN 4 8 1.48 6 A A O HD22 PHE ASN 4 8 1.46 7 A A O HD22 PHE ASN 4 8 1.54 8 A A O HD22 PHE ASN 4 8 1.46 8 A A O O ARG GLU 9 13 2.14 9 A A O HD22 PHE ASN 4 8 1.50 11 A A O HD22 PHE ASN 4 8 1.55 12 A A HZ2 OD1 LYS ASP 6 16 1.40 12 A A O HD22 PHE ASN 4 8 1.47 13 A A O HD22 PHE ASN 4 8 1.47 14 A A O HD22 PHE ASN 4 8 1.46 15 A A O HD22 PHE ASN 4 8 1.53 16 A A O HD22 PHE ASN 4 8 1.56 1 A VAL 2 -160.94 27.26 1 A PHE 4 -142.64 13.99 1 A PHE 5 -140.55 -38.88 1 A LYS 6 -79.38 20.12 1 A ARG 7 -131.10 -62.31 1 A PRO 11 -59.20 -71.26 1 A LEU 12 -41.79 -87.34 1 A ASP 15 -93.27 -79.37 1 A GLU 18 -48.29 -80.91 2 A VAL 2 -161.09 27.64 2 A PHE 5 -136.71 -40.19 2 A ARG 7 -129.01 -61.84 2 A PRO 11 -54.06 -71.10 2 A LEU 12 -41.16 -92.09 2 A ASP 15 -93.37 -78.21 2 A GLU 17 -60.26 96.69 3 A VAL 2 -160.75 24.42 3 A PHE 5 -139.88 -37.62 3 A LYS 6 -79.23 20.05 3 A ARG 7 -131.48 -62.09 3 A PRO 11 -56.89 -72.42 3 A LEU 12 -38.90 -89.21 3 A ASP 15 -93.36 -102.52 4 A VAL 2 -158.08 27.36 4 A PHE 5 -138.95 -37.93 4 A LYS 6 -79.10 21.57 4 A ARG 7 -131.87 -61.45 4 A PRO 11 -57.82 -71.23 4 A LEU 12 -40.78 -88.34 4 A ASP 15 -92.51 -78.61 5 A VAL 2 -160.90 24.19 5 A PHE 5 -140.86 -38.06 5 A ARG 7 -130.48 -61.63 5 A PRO 11 -56.66 -71.84 5 A LEU 12 -42.97 -89.75 5 A ASP 15 -91.44 -79.24 5 A ASP 16 -49.80 163.34 5 A GLU 17 -67.61 84.19 6 A VAL 2 -158.21 27.63 6 A PHE 5 -135.39 -36.54 6 A LYS 6 -78.67 20.47 6 A ARG 7 -131.96 -63.03 6 A PRO 11 -59.10 -71.09 6 A LEU 12 -41.20 -87.34 6 A ASP 15 -89.68 -77.34 7 A VAL 2 -158.20 27.41 7 A PHE 5 -138.52 -37.56 7 A LYS 6 -78.96 20.38 7 A ARG 7 -130.68 -61.75 7 A PRO 11 -57.88 -72.17 7 A LEU 12 -42.60 -90.28 7 A ASP 15 -92.73 -78.82 8 A VAL 2 -158.36 27.80 8 A PHE 5 -135.31 -36.59 8 A LYS 6 -78.47 20.28 8 A ARG 7 -131.47 -62.92 8 A PRO 11 -61.86 -72.20 8 A LEU 12 -43.16 -78.60 8 A ASP 15 -95.50 -79.16 9 A VAL 2 -158.43 27.06 9 A PHE 5 -135.29 -36.03 9 A ARG 7 -130.77 -63.64 9 A PRO 11 -58.96 -72.67 9 A LEU 12 -37.96 -88.77 9 A ASP 15 -88.53 -102.24 10 A VAL 2 -160.90 24.18 10 A PHE 5 -140.91 -38.02 10 A ARG 7 -130.60 -61.68 10 A PRO 11 -56.85 -71.74 10 A LEU 12 -42.99 -90.14 10 A ASP 15 -91.56 -79.27 10 A GLU 17 -68.68 91.20 10 A GLU 18 -46.29 -79.24 11 A VAL 2 -160.77 22.66 11 A PHE 5 -140.67 -39.63 11 A LYS 6 -79.39 21.92 11 A ARG 7 -130.39 -60.99 11 A PRO 11 -56.47 -70.91 11 A LEU 12 -42.55 -87.90 11 A ASP 15 -93.03 -77.92 11 A GLU 18 -48.65 -75.59 12 A VAL 2 -158.09 28.04 12 A PHE 5 -137.26 -37.52 12 A LYS 6 -78.92 24.50 12 A ARG 7 -136.10 -63.16 12 A PRO 11 -60.24 -71.73 12 A LEU 12 -36.37 -86.39 12 A GLU 14 -69.94 74.49 12 A ASP 15 -90.42 -102.47 12 A GLU 17 -59.96 109.41 13 A VAL 2 -160.80 24.21 13 A PHE 5 -137.30 -38.29 13 A ARG 7 -130.38 -61.25 13 A PRO 11 -58.65 -72.23 13 A LEU 12 -41.19 -92.31 13 A ASP 15 -91.73 -80.43 14 A VAL 2 -158.32 27.58 14 A PHE 5 -135.64 -36.54 14 A ARG 7 -131.13 -62.74 14 A PRO 11 -59.72 -70.84 14 A LEU 12 -43.55 -84.30 14 A ASP 15 -90.88 -77.58 14 A GLU 18 -49.68 -73.85 15 A VAL 2 -160.98 23.26 15 A PHE 5 -140.78 -38.74 15 A ARG 7 -130.69 -61.87 15 A PRO 11 -56.67 -72.52 15 A LEU 12 -41.04 -90.33 15 A ASP 15 -93.46 -78.92 15 A GLU 17 -68.83 91.57 16 A VAL 2 -160.82 24.36 16 A PHE 5 -139.95 -37.69 16 A ARG 7 -131.14 -61.52 16 A PRO 11 -57.62 -71.93 16 A LEU 12 -42.31 -91.00 16 A ASP 15 -91.20 -79.67 minimized average SOLUTION STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE INTEGRIN ALPHA-IIB SUBUNIT 1 N N A ASN 8 A ASN 8 HELX_P A GLU 13 A GLU 13 1 1 6 CELL ADHESION HELIX-TURN, CELL ADHESION ITA2B_HUMAN UNP 1 P08514 1020 1039 1DPK 1 20 P08514 A 1 1 20 1 P 1